Mitochondrial Function and Dysfunction in Female Fertility: Biological Mechanisms, Genetic Determinants, and Therapeutic Opportunities - A Review.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing biological mechanisms and potential therapeutics without systematic review methods or new primary data
PubMed 42082824 · doi:10.1007/s43032-026-02113-8
What was done
This narrative review synthesized current literature on mitochondrial bioenergetics, redox signaling, and dynamics in female fertility, oocyte competence, and ovarian longevity. It evaluated disruptions caused by aging, obesity, and metabolic stress (such as in polycystic ovary syndrome) and summarized mechanistic evidence for mitochondria-targeted antioxidants (e.g., melatonin, resveratrol, N-acetylcysteine, coenzyme Q10) and metabolic modulators (e.g., metformin, dapagliflozin, GLP-1 receptor agonists).
What was found
The abstract reports no numerical data, effect estimates, or primary experimental findings. It qualitatively describes how mitochondrial dysfunction (oxidative phosphorylation impairment, mtDNA instability, altered dynamics) compromises granulosa cell support and oocyte maturation, and summarizes how targeted antioxidant and metabolic therapies may restore bioenergetics.
Why it matters
The paper frames ovarian mitochondrial reprogramming as an active therapeutic strategy to preserve fertility and extend reproductive healthspan rather than relying on non-specific damage mitigation.
Limits
The paper is a narrative review without systematic search protocols, risk-of-bias evaluation, or meta-analytic data. No human clinical trial results, sample sizes, or quantitative outcome measures (such as clinical pregnancy or live-birth rates) are reported in the abstract.
Cited by
- supports Mitochondrial dysfunction driven by oxidative stress is a major reason why egg quality declines with unhealthy habits, and infertility is often an early sign of mitochondrial performance issues.